Clinical Trial Update: Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine [Phase 3]

View source ↗

Summary

Phase 3 trial updating the efficacy and safety of intravenous rigosertib in myelodysplastic syndrome patients with excess blasts who progressed after azacitidin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia with Excess Blasts
• Cytopenia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts | Phase 3 | Status: COMPLETED